Filing Flows › Integrated Biopharma (INBP) › Q4 FY25
Integrated Biopharma (INBP) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Sep 23, 2025
Integrated Biopharma (INBP) reported revenue of $14.2M for the fourth quarter fiscal 2025 (Q4 FY25), +11% from a year earlier and +2% from the quarter before. Operating margin was 4.2%, net loss $178K (1.3% of revenue).
Integrated Biopharma, Q4 FY25: revenue $14.2M (+11% year over year), operating margin 4.2%, net loss $178K, operating cash flow $591K. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.2M | +2% | +11% |
| Operating profit | $589K | -20% | — |
| Net earnings | −$178K | -129% | — |
| Operating cash flow | $591K | -4% | — |
What changed
Revenue was $14.2M in Q4 FY25, up 11% year over year and up 2% from the previous quarter. Contract Manufacturing was the largest line at 96% of revenue.
Gross margin was 10.4%, up 0.3 points from a year earlier. Operating profit was $589K, a 4.2% margin (up 1.0 points year over year). Of the extra revenue versus a year earlier, 13% reached operating profit, above the 3% margin then. Operating expenses fell 0% while revenue rose 11%. The quarter ended with a net loss of $178K, after a profit of $611K the previous quarter.
Operating cash flow was $591K. Non-cash charges added back $71K of depreciation and $44K of share-based compensation. Working capital and other items added $654K. Capital expenditures of −$10K left free cash flow of $601K.
Questions
What was Integrated Biopharma's revenue in the fourth quarter fiscal 2025?
Integrated Biopharma (INBP) reported revenue of $14.2M for the fourth quarter fiscal 2025 (Q4 FY25), +11% from a year earlier and +2% from the quarter before.
Was Integrated Biopharma profitable in the fourth quarter fiscal 2025?
Operating profit was $589K (4.2% of revenue) and net loss $178K.